TCBIO (Texas Capital Bancshares, Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B)
Insider Trading Activity
Every open-market purchase and sale reported by TCBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-16 | John Matthew Scurlock | Chief Financial Officer | Buy | — | — |
| 2026-06-10 | Anna M Alvarado | Chief Legal Officer | Sell | — | — |
| 2026-06-08 | Rob C Holmes | Chairman, President and CEO | Sell | — | — |
| 2026-04-29 | Ranjana B Clark | Director | A | — | — |
| 2026-04-29 | STEVE ROSENBERG | Director | A | — | — |
| 2026-04-29 | Jonathan Baliff | Director | A | — | — |
| 2026-04-29 | Thomas E Long | Director | A | — | — |
| 2026-04-29 | Dale W Tremblay | Director | A | — | — |
| 2026-04-29 | Mark W Midkiff | Director | A | — | — |
| 2026-04-29 | Laura L Whitley | Director | A | — | — |
| 2026-04-29 | David S. Huntley | Director | A | — | — |
| 2026-04-29 | Paola M Arbour | Director | A | — | — |
| 2026-04-23 | Paola M Arbour | Director | M | — | — |
| 2026-04-23 | Jonathan Baliff | Director | M | — | — |
| 2026-04-23 | Ranjana B Clark | Director | M | — | — |
| 2026-04-23 | David S. Huntley | Director | M | — | — |
| 2026-04-23 | Thomas E Long | Director | M | — | — |
| 2026-04-23 | Mark W Midkiff | Director | M | — | — |
| 2026-04-23 | Elysia Holt Ragusa | Director | M | — | — |
| 2026-04-23 | STEVE ROSENBERG | Director | M | — | — |
| 2026-04-23 | ROBERT W STALLINGS | Director | M | — | — |
| 2026-04-23 | Dale W Tremblay | Director | M | — | — |
| 2026-04-23 | Laura L Whitley | Director | M | — | — |
| 2026-04-23 | Charles S Hyle | Director | M | — | — |
| 2026-03-12 | Paola M Arbour | Director | Buy | — | — |
| 2026-03-09 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-03-05 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-03-03 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-02-25 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-02-23 | Rob C Holmes | Chairman, President and CEO | MIXED | — | — |
| 2026-02-19 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-02-17 | Anna M Alvarado | Chief Legal Officer | MIXED | — | — |
| 2026-02-17 | John Matthew Scurlock | Chief Financial Officer | MIXED | — | — |
| 2026-02-17 | John W Cummings | Chief Administrative Officer | MIXED | — | — |
| 2026-02-17 | Rob C Holmes | Chairman, President and CEO | MIXED | — | — |
| 2026-02-10 | Anna M Alvarado | Chief Legal Officer | MIXED | — | — |
| 2026-02-10 | John W Cummings | Chief Administrative Officer | MIXED | — | — |
| 2026-02-10 | John Matthew Scurlock | Chief Financial Officer | MIXED | — | — |
| 2026-02-10 | Ellen Detrich | Controller | MIXED | — | — |
| 2026-02-10 | Rob C Holmes | Chairman, President and CEO | MIXED | — | — |
| 2026-02-06 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-02-04 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-02-02 | ROBERT W STALLINGS | Director | Buy | — | — |
| 2026-01-30 | John Matthew Scurlock | Chief Financial Officer | MIXED | — | — |
| 2026-01-30 | David W Oman | Chief Risk Officer | MIXED | — | — |
| 2026-01-30 | John W Cummings | Chief Administrative Officer | MIXED | — | — |
| 2026-01-30 | Rob C Holmes | Chairman, President and CEO | MIXED | — | — |
| 2026-01-30 | Anna M Alvarado | Chief Legal Officer | MIXED | — | — |
| 2026-01-27 | Laura L Whitley | Director | Buy | — | — |
| 2026-01-27 | ROBERT W STALLINGS | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 536,000 | — |
| — | Chairman, President and CEO | 435,316 | — |
| — | CEO and President | 77,858 | — |
| — | Chief Financial Officer | 70,129 | — |
| — | Chief Legal Officer | 23,810 | — |
| — | Chief Financial Officer | 22,278 | — |
| — | Director | 21,304 | — |
| — | Director | 18,795 | — |
| — | Director | 17,995 | — |
| — | Chief Risk Officer | 16,462 | — |
| — | Director | 16,020 | — |
| — | Chief Administrative Officer | 13,709 | — |
| — | Director | 12,468 | — |
| — | Director | 12,173 | — |
| — | Director | 11,265 | — |
| — | Director | 9,631 | — |
| — | Controller | 8,855 | — |
| — | Director | 8,341 | — |
| — | Director | 7,023 | — |
| — | Director | 2,804 | — |
| — | Chief Risk Officer | 2,388 | — |
| — | Director | 1,670 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TCBIO quote page; the site-wide leaderboard is on the insider transactions hub.